depot octreotide

Phase 2

Eli Lilly and Company (LLY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Carcinoma

View Full Landscape

Drug Information

Target Indication

Carcinoma

Clinical Trial

NCT00781911

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/30/2025

Oczyesa

Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

View on EMA

EMA12/2/2022

Mycapssa

Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

somatropin, rDNA origin, for injectionPhase 3

Growth Disorder

Ultra-Rapid LisproPhase 3

Type 1 Diabetes Mellitus